DelveInsightによると、IgA腎症市場は2034年までに大幅に成長すると予想されています | Visterra、Chinook Therapeutics

IgA Nephropathy Market Expected to Grow Significantly by 2034, DelveInsight's report titled "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of IgA Nephropathy, including its historical and projected epidemiology, along with market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

For detailed insights into the IgA Nephropathy market outlook, drug adoption, treatment landscape, and epidemiology trends, click here: IgA Nephropathy Market Forecast-https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Highlights from the IgA Nephropathy Market Report:

• The IgA Nephropathy market was valued at approximately USD 730 million in 2024 and is projected to expand at a notable CAGR over the study period (2020-2034).
• In May 2025, Otsuka Pharmaceuticals disclosed that the FDA has accepted the Biologics License Application (BLA) for sibeprenlimab, an APRIL (a proliferation-inducing ligand) inhibitor in development for treating immunoglobulin A nephropathy (IgAN). This follows the FDA's 2024 Breakthrough Therapy Designation for the drug. The BLA is supported by results from the Phase III VISIONARY trial. GlobalData notes that the priority review highlights sibeprenlimab's potential edge over existing treatments and its suitability for addressing IgAN's complexities. If approved, it could be the first therapy to modify the disease while tackling both clinical and practical management challenges.
• In March 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) shared preliminary results from Part 2 of its Phase 1/2 trial for ARO-C3, an investigational RNA interference (RNAi) therapy designed to reduce liver production of complement component 3 (C3) for potential use in various complement-mediated conditions.
• In November 2024, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical Co., Ltd. announced their intention to file a Biologics License Application (BLA) in the U.S. for sibeprenlimab, a potential treatment for adults with immunoglobulin A nephropathy (IgA nephropathy), in the first half of 2025. This follows a recent FDA meeting to discuss encouraging interim data from the Phase 3 VISIONARY trial (NCT05248646).
• In January 2024, Vera Therapeutics, Inc. (Nasdaq: VERA), a biotech firm advancing clinical-stage therapies for serious immunological disorders, revealed the appointment of two experienced industry experts to drive its drug development efforts. This includes their late-stage candidate, atacicept, currently in a Phase 3 trial for IgA nephropathy (IgAN). Robert M. Brenner, M.D., has been named Chief Medical Officer, replacing Dr. Celia Lin, M.D., and William D. Turner has taken the role of Chief Development Officer.
• In 2024, the IgA Nephropathy (IgAN) market in the US was estimated at around USD 455 million, with growth anticipated from new therapies.
• The combined market size for the EU4 and the UK reached approximately USD 150 million in 2024, accounting for about 21% of the total revenue in the 7MM, with further expansion expected by 2034.
• In 2024, Germany dominated the IgAN market in the EU4 and UK with roughly USD 45 million in sales, trailed by France at about USD 35 million and Italy at nearly USD 30 million.
• Japan's IgAN market was valued at around USD 125 million in 2024, with projected growth from 2025 to 2034.
• DelveInsight estimates that there were about 415,000 prevalent cases of IgA Nephropathy (IgAN) across the 7MM in 2024, with diagnosed cases anticipated to increase at a CAGR of 0.6% by 2034.
• The United States had approximately 133,000 diagnosed prevalent cases of IgA Nephropathy (IgAN) in 2024, with numbers expected to rise by 2034.
• Among the EU4 and UK, Germany reported the highest number of diagnosed prevalent cases of IgA Nephropathy (IgAN) in 2024, at around 30,000, while Spain had the lowest, with about 5,000.
• Japan recorded the largest number of diagnosed prevalent cases of IgA Nephropathy (IgAN) in the 7MM in 2024, nearly 175,000, with an upward trend projected by 2034.
• In 2024, France documented about 16,000 diagnosed prevalent cases of IgA Nephropathy (IgAN) in males and 8,000 in females, with both figures expected to grow by 2034.
• Leading IgA Nephropathy Companies: Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA Proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others.
• Key IgA Nephropathy Therapies: VANRAFIA (atrasentan), FILSPARI (sparsentan), TARPEYO/KINPEYGO (budesonide), Povetacicept (ALPN-303), Atacicept, Zigakibart (FUB523), Sibeprenlimab, Atrasentan, LNP023, Research Programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others.
• Epidemiology analysis by gender indicates that IgAN is more common in males than females, with global prevalence in men being roughly twice that in women.
• The IgA Nephropathy market is poised for growth due to rising disease prevalence, increased awareness, and the launch of multiple pipeline products, which will transform market dynamics.

IgA Nephropathy Overview IgA nephropathy, also referred to as Berger's disease, is a kidney condition involving the accumulation of the antibody immunoglobulin A (IgA) in the kidneys. This leads to inflammation and harm to the glomeruli, the small filters in the kidneys. It ranks as one of the most frequent types of glomerulonephritis, an inflammatory condition affecting the glomeruli.

Get a Free Sample for the IgA Nephropathy Market Forecast, Size & Share Analysis Report- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

IgA Nephropathy Epidemiology The epidemiology segment examines historical, current, and future trends in the seven major markets (7MM) from 2020 to 2034. It identifies drivers of trends through studies and expert opinions, offering a thorough breakdown of the diagnosed patient pool and upcoming patterns.

IgA Nephropathy Epidemiology Segmentation: The report segments the epidemiology of IgA Nephropathy in the 7MM from 2020-2034 into:

• Total Prevalence of IgA Nephropathy
• Prevalent Cases of IgA Nephropathy by Severity
• Gender-Specific Prevalence of IgA Nephropathy
• Diagnosed Cases of Episodic and Chronic IgA Nephropathy

Download the report to explore factors influencing IgA Nephropathy epidemiology trends @ IgA Nephropathy Epidemiology Forecast-https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

IgA Nephropathy Drug Adoption and Pipeline Developments This section analyzes the uptake rate of new drugs in the IgA Nephropathy market, including those recently introduced or anticipated during the study period. It covers market adoption by drug, patient uptake by therapy, and sales figures. The therapeutics evaluation identifies drugs with the fastest adoption and underlying reasons. It also compares therapies based on market share. Additionally, the report details pipeline activities, offering insights into various candidates at different stages and involved companies. It covers recent events like partnerships, mergers, acquisitions, licensing, patents, and other updates for emerging treatments.

IgA Nephropathy Therapies and Key Companies

• VANRAFIA (atrasentan): Novartis
• FILSPARI (sparsentan): Travere Therapeutics
• TARPEYO/KINPEYGO (budesonide): Asahi Kasei (Calliditas Therapeutics)
• Povetacicept (ALPN-303): Vertex Pharmaceuticals
• Atacicept: Vera Therapeutics
• Zigakibart (FUB523): Novartis
• Sibeprenlimab: Visterra
• Atrasentan: Chinook Therapeutics
• LNP023: Novartis Pharmaceuticals
• Research Programme: IgA Proteases Selecta Biosciences
• AP 305: Shanghai Alebund Pharmaceuticals
• ADR-001: Rohto Pharmaceutical
• MY 008: Wuhan Createrna Science and Technology
• SHR-2010: Guangdong Hengrui Pharmaceutical
• IONIS FB: LRx Ionis Pharmaceuticals
• HR19042: Jiangsu HengRui Medicine Co., Ltd.
• Sparsentan: Travere Therapeutics
• HR19042: Jiangsu HengRui Medicine Co., Ltd.

Learn more about therapies poised to capture significant IgA Nephropathy market share @ IgA Nephropathy Treatment Landscape- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

IgA Nephropathy Market Drivers

• Rising prevalence of IgA Nephropathy (IgAN) and increased government efforts to raise awareness are key factors propelling the market.

IgA Nephropathy Market Barriers

• Challenges include limited understanding of disease mechanisms, underreported and undiagnosed cases, and other obstacles hindering growth.

Scope of the IgA Nephropathy Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key IgA Nephropathy Companies: Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA Proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others.
• Key IgA Nephropathy Therapies: VANRAFIA (atrasentan), FILSPARI (sparsentan), TARPEYO/KINPEYGO (budesonide), Povetacicept (ALPN-303), Atacicept, Zigakibart (FUB523), Sibeprenlimab, Atrasentan, LNP023, Research Programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others.
• IgA Nephropathy Therapeutic Assessment: Current marketed therapies and emerging treatments for IgA Nephropathy.
• IgA Nephropathy Market Dynamics: Drivers and barriers in the IgA Nephropathy market.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and market entry strategies.
• IgA Nephropathy Unmet Needs, Key Opinion Leader Views, Analyst Insights, and Market Access and Reimbursement.

To learn about companies active in the IgA Nephropathy treatment space, visit @ IgA Nephropathy Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

1. Introduction to the IgA Nephropathy Market Report
2. Executive Summary for IgA Nephropathy
3. SWOT Analysis of IgA Nephropathy
4. Overview of IgA Nephropathy Patient Share (%) at a Glance
5. Overview of IgA Nephropathy Market at a Glance
6. Background and Overview of IgA Nephropathy Disease
7. IgA Nephropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of IgA Nephropathy
9. Current Treatment and Medical Practices for IgA Nephropathy
10. Unmet Needs in IgA Nephropathy
11. Emerging Therapies for IgA Nephropathy
12. IgA Nephropathy Market Outlook
13. Country-Wise IgA Nephropathy Market Analysis (2020-2034)
14. Market Access and Reimbursement for IgA Nephropathy Therapies
15. IgA Nephropathy Market Drivers
16. IgA Nephropathy Market Barriers
17. IgA Nephropathy Appendix
18. IgA Nephropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports

IgA Nephropathy (IgAN) - Pipeline Insight, 2025

DelveInsight’s, “IgA Nephropathy Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. IgA Nephropathy Companies are Chinook Therapeutics , Guangdong Hengrui Pharmaceutical Co., Ltd. , Takeda , Visterra , Novartis Pharmaceuticals , Wuhan Createrna Science and Technology , Jiangsu HengRui Medicine Co., Ltd. , Takeda ,  Selecta Biosciences , Shanghai Alebund Pharmaceuticals , and  others.

IgA Nephropathy (IgAN) - Epidemiology Forecast to 2034

DelveInsight’s, “IgA Nephropathy Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

About DelveInsight

DelveInsight is a premier market research and advisory company focused on condition-specific intelligence and therapeutic market evaluations. Their reports blend real-world data, clinical trial results, and expert discussions to provide thorough industry knowledge.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/